| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Piperlongumine (also called Piplartine), an alkaloid from long pepper fruit -Piperlongumine is a bioactive alkaloid derived from the long pepper (Piper longum) – Piperlongumine has been shown to selectively increase ROS levels in cancer cells. -NLRP3 inhibitor? -TrxR inhibitor (major antioxidant system) to increase ROS in cancer cells -ic50 cancer cells maybe 2-10uM, normal cells maybe exceeding 20uM. Available from mcsformulas.com -(Long Pepper, 500mg/Capsule)- 1 capsule 3 times daily with food -Piperlongumine Pro Liposomal, 40 mg-take 1 capsule daily with plenty of water, after a meal -Note half-life 30–60 minutes BioAv poor aqueous solubility and bioavailability Pathways: - induce ROS production in cancer cells likely at any dose. Effect on normal cells is inconclusive. - ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, Prx, - Lowers some AntiOxidant markers/ defense in Cancer Cells: but mostly raises NRF2 (raises antiO defense), TrxR↓(*important), GSH↓ Catalase↓ HO1↓ GPx↓ - Very little indication of raising AntiOxidant defense in Normal Cells: GSH↑, - lowers Inflammation : NF-kB↓, COX2↓, conversely p38↑, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓ - inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMP2↓, MMP9↓, VEGF↓, NF-κB↓, CXCR4↓, ERK↓ - reactivate genes thereby inhibiting cancer cell growth : HDAC↓(few reports), DNMT1↓, DNMT3A↓, EZH2↓, P53↑, HSP↓, Sp proteins↓, - cause Cell cycle arrest : TumCCA↑, cyclin D1↓, CDK2↓, CDK4↓, CDK6↓, - inhibits Migration/Invasion : TumCMig↓, TumCI↓, ERK↓, EMT↓, - small indication of inhibiting glycolysis : HIF-1α↓, cMyc↓, LDH↓, HK2↓, - inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, EGFR↓, - Others: PI3K↓, AKT↓, JAK↓, STAT↓, β-catenin↓, ERK↓, JNK, - Synergies: chemo-sensitization, RadioSensitizer, Others(review target notes), Neuroprotective, Cognitive, Hepatoprotective, CardioProtective, - Selectivity: Cancer Cells vs Normal Cells
|
| Source: |
| Type: |
| Lipid peroxidation is a chain reaction process in which free radicals (often reactive oxygen species, or ROS) attack lipids containing carbon-carbon double bonds, especially polyunsaturated fatty acids. This attack results in the formation of lipid radicals, peroxides, and subsequent breakdown products. Lipid peroxidation can cause damage to cell membranes, leading to increased permeability and disruption of cellular functions. This damage can initiate a cascade of events that may contribute to carcinogenesis. The byproducts of lipid peroxidation, such as malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), can form adducts with DNA, leading to mutations. These mutations can disrupt normal cellular processes and contribute to the development of cancer. Lipid peroxidation damages cell membranes, disrupts cellular functions, and can trigger inflammatory responses. It is a marker of oxidative stress and is implicated in many chronic diseases. Negative Prognostic Indicator: In many cancers, high levels of lipid phosphates, particularly S1P, are associated with poor prognosis, indicating a more aggressive tumor phenotype and potential resistance to therapy. Mixed Evidence: The prognostic significance of lipid phosphates can vary by cancer type, with some studies showing that their expression may not always correlate with adverse outcomes. |
| 2958- | PL, | Natural product piperlongumine inhibits proliferation of oral squamous carcinoma cells by inducing ferroptosis and inhibiting intracellular antioxidant capacity |
| - | in-vitro, | Oral, | HSC3 |
| 1951- | PL, | Piperlongumine Analogs Promote A549 Cell Apoptosis through Enhancing ROS Generation |
| - | in-vitro, | Lung, | A549 |
| 1944- | PL, | Piperlongumine, a Novel TrxR1 Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cells by ROS-Mediated ER Stress |
| - | in-vitro, | HCC, | HUH7 | - | in-vitro, | HCC, | HepG2 |
| 1947- | PL, | Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer |
| - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | GC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:134 Target#:453 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid